Editorial Board for section 'Leukemias'

Please see the section webpage for more information on this section.

Please note that the order in which the Editors appear on this page is alphabetical, and follows the structure of the editorial board presented on the MDPI website under information for editors: editorial board responsibilities.

Members


Website
Section Board Member
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Interests: experimental therapeutics; acute leukemias; myeloproliferative diseases

Website
Section Board Member
Massachusetts General Hospital Cancer Center, Harvard Medical School, 0 Emerson Place, Suite 118, Boston, MA 02114, USA
Interests: IDH-inhibition; aurora kinase inhibition; FLT3 inhibition; antibody-drug conjugates; novel therapeutic approaches; acute leukemias

Website
Section Board Member
Tenured Professor of Pathology Chair, Department of Pathology P.L. Foster School of Medicine Texas Tech University Health Sciences Center, El Paso, TX, USA
Interests: myeloid neoplasms; spleen pathology; lymphoid neoplasms

Website1 Website2
Section Board Member
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
Interests: acute myeloid leukemia; aplastic anemia; myelodysplastic syndromes; myeloproliferative neoplasms; paroxysmal nocturnal hemoglobinuria


Section Board Member
Department of Oncology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
Interests: acute myeloid leukemia; normal and leukemic stem cells; hematopoietic differentiation; cell differentiation therapy; targeted therapy; CD123 targeting
Special Issues, Collections and Topics in MDPI journals

Website
Section Board Member
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
Interests: acute myeloid leukemia; antibody-based therapy; CD33; clinical trials; minimal residual disease
Special Issues, Collections and Topics in MDPI journals

Website
Section Board Member
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Interests: role of angiogenesis in promoting the growth of hematological malignancies; screening anti-angiogenic and other biological agents for effects on clinically relevant human leukemia in vivo; early stage clinical trials for acute leukemia

Website
Section Board Member
Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT, USA.
Interests: hematologic neoplasms; translational medical research; MDS; AML; clinical research; novel therapies
Back to TopTop